Clinical Trials

250 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06651970 2026-04-15

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Phase 4 Recruiting

60 enrolled

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

NCT06943872 2026-04-15

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

630 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06090539 2026-04-14

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Phase 1/2 Recruiting

308 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin

NCT04623541 2026-04-13

EPCORE™ CLL-1

195 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05283720 2026-04-13

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06149286 2026-04-13

OLYMPIA-5

470 enrolled

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT06191744 2026-04-13

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT06564038 2026-04-13

Soundtrack-E

Phase 1/2 Recruiting

408 enrolled

Phase 1/2 Not yet recruiting

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT07520006 2026-04-13

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

150 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04542824 2026-04-08

EPCORE™ NHL-3

78 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-04-08

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT06230224 2026-04-08

OLYMPIA-4

216 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06508658 2026-04-08

EPCORE DLBCL-4

379 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07029737 2026-04-08

SOUND-MCL

55 enrolled

Lymphoma, Mantle-Cell

NCT05139017 2026-04-07

waveLINE-003

Phase 2/3 Recruiting

290 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04673617 2026-04-03

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Completed

45 enrolled

Lymphoma, Lymphoma, Non-Hodgkin

NCT05533775 2026-04-03

iMATRIX GLO

Phase 1/2 Recruiting

65 enrolled

Recurrence

NCT06084936 2026-04-02

GLOBRYTE

182 enrolled

Lymphoma

NCT06890884 2026-04-02

MK-2140-011

594 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04824092 2026-04-01

frontMIND

899 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07409428 2026-04-01

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

240 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04529772 2026-03-31

ESCALADE

611 enrolled

Phase 1 Not yet recruiting

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07226843 2026-03-31

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

360 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT07139873 2026-03-27

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

250 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04384484 2026-03-24

LOTIS 5

440 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05888493 2026-03-24

LEDA

109 enrolled

Lymphoma, Follicular, Recurrence

NCT07015242 2026-03-24

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

65 enrolled

Lymphoma

NCT05100862 2026-03-18

MAHOGANY

780 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Phase 3 Withdrawn